Reported 2 days ago
The U.S. pharmaceutical industry is anticipating a significant surge in domestic manufacturing, fueled by over $270 billion in investments from major companies like Johnson & Johnson and Eli Lilly. However, many of these plans are not new and have been shaped by uncertainties stemming from the COVID-19 pandemic, patent expirations, and looming tariffs on imported pharmaceuticals. Experts caution that while construction activity is set to rise, the industry faces mounting challenges such as rising tariffs impacting material costs and a potential labor shortage, leading to concerns about timelines and project completion.
Source: YAHOO